ovalbumin and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

ovalbumin has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for ovalbumin and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

Article	Year
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007, Volume: 21, Issue:9 Chaperone proteins are effective antitumor vaccines when purified from a tumor source, some of which are in clinical trials. Such vaccines culminate in tumor-specific T cell responses, implicating the role of adaptive immunity. We have developed a rapid and efficient procedure utilizing an isoelectric focusing technique to obtain vaccines from tumor or normal tissues called chaperone-rich cell lysate (CRCL). Tumor-associated peptides, the currency of T cell-mediated anticancer immunity, are believed to be purveyed by chaperone vaccines. Our purpose was to demonstrate our ability to manipulate the peptide antigen repertoire of CRCL vaccines as a novel anticancer strategy. Our methods allow us to prepare "designer" CRCL, utilizing the immunostimulation activity and the carrying capacity of CRCL to quantitatively acquire and deliver exogenous antigenic peptides (e.g., derived from the oncogenic BCR/ABL protein in chronic myelogenous leukemia). Using fluorescence-based and antigen-presentation assays, we determined that significant quantities of exogenously added peptide could accumulate in "designer" CRCL and could stimulate T cell activation. Further, we concluded that peptide-embedded CRCL, devoid of other antigens, could generate potent immunity against pre-established murine leukemia. Designer CRCL allows for the development of personalized vaccines against cancers expressing known antigens, by embedding antigens into CRCL derived from normal tissue. Topics: Animals; Bone Marrow Cells; Calbindin 2; Cancer Vaccines; Cells, Cultured; Dendritic Cells; Drug Screening Assays, Antitumor; Drug Synergism; Egg Proteins; Female; Fusion Proteins, bcr-abl; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Immunotherapy, Active; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Chaperones; Oligopeptides; Ovalbumin; Peptide Fragments; S100 Calcium Binding Protein G; Tissue Extracts	2007

Article

Year

Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2007, Volume: 21, Issue:9

Chaperone proteins are effective antitumor vaccines when purified from a tumor source, some of which are in clinical trials. Such vaccines culminate in tumor-specific T cell responses, implicating the role of adaptive immunity. We have developed a rapid and efficient procedure utilizing an isoelectric focusing technique to obtain vaccines from tumor or normal tissues called chaperone-rich cell lysate (CRCL). Tumor-associated peptides, the currency of T cell-mediated anticancer immunity, are believed to be purveyed by chaperone vaccines. Our purpose was to demonstrate our ability to manipulate the peptide antigen repertoire of CRCL vaccines as a novel anticancer strategy. Our methods allow us to prepare "designer" CRCL, utilizing the immunostimulation activity and the carrying capacity of CRCL to quantitatively acquire and deliver exogenous antigenic peptides (e.g., derived from the oncogenic BCR/ABL protein in chronic myelogenous leukemia). Using fluorescence-based and antigen-presentation assays, we determined that significant quantities of exogenously added peptide could accumulate in "designer" CRCL and could stimulate T cell activation. Further, we concluded that peptide-embedded CRCL, devoid of other antigens, could generate potent immunity against pre-established murine leukemia. Designer CRCL allows for the development of personalized vaccines against cancers expressing known antigens, by embedding antigens into CRCL derived from normal tissue.

Topics: Animals; Bone Marrow Cells; Calbindin 2; Cancer Vaccines; Cells, Cultured; Dendritic Cells; Drug Screening Assays, Antitumor; Drug Synergism; Egg Proteins; Female; Fusion Proteins, bcr-abl; HSP72 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Immunotherapy, Active; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Chaperones; Oligopeptides; Ovalbumin; Peptide Fragments; S100 Calcium Binding Protein G; Tissue Extracts

2007